NEXIGN
Nexign (a part of ICS Holding LLC), a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, today announced the successful migration of subscribers in all branch offices of the Russian mobile broadband services provider Yota to the Nexign Network Monetisation Suite – a versatile solution for real-time rating, charging and policy control across all network services.
Yota was the first operator to offer its customers communication bundles configurable to minutes and gigabytes, as well as differentiated payment for various types of traffic. Yota’s existing solution did not enable horizontal scaling. The company needed a scalable and flexible instrument for charging and policy control inside the network.
To increase effectiveness of its internal processes, Yota opted for Nexign Network Monetisation Suite, which included solutions like PCRF (Policy and Charging Rules Function), RCAF (RAN congestion awareness function) and UDR (User Data Repository).
As a result, Yota received future-proof solution, which fully met the needs of the mobile operator. Yota reduced the total cost of ownership (TCO) by 10-20% by saving on additional third-party licenses. Use of PCRF function enabled the company to reduce time to market (TTM) by 20% and increase the fault tolerance by 40%, which allows the operator to deliver great customer service and stand out from competition. Nexign’s solution helps Yota provide customer services even in the conditions of congestion.
“The jointed project with Nexign allowed us to launch unique product for the telco market called 'The communications constructor' and maintain high quality of our services while increasing the number of customers. In the past six months the new solution underwent unprecedented stress test. Due to the pandemic, traffic from business apps inside the network has grown 2.5 times,” said Andrey Zhikin, IT Director of Yota .
“This project is the first time when Nexign implemented its solution in a telecom operator that uses a third-party billing system,” said Alexey Vedin, Director of Network Monetisation Products at Nexign . “Integration with Yota’s BSS systems was carried out with no impact on Yota’s customers and without any failures or service interruption. No additional modifications were required on the part of billing or other systems – all the needs of the operator were covered by the capabilities of Nexign’s solution.”
Learn more about Nexign’s products and services here: https://nexign.com/en .
About Nexign
Nexign , a part of Intellectual Computer Systems Holding (https://x-holding.ru/ ) and a leading Business Support System (BSS) and Internet of Things (IoT) solutions provider, has been delivering pragmatic, value-driven, high-performance product solutions since 1992. Nexign has an experience of transformational projects of all scales, and a proven track record of achieving revenue boosts for CSPs through systems consolidation and a faster go-to-market time for new services after modernisation.
Headquartered in St. Petersburg, Nexign employs 1,800 people in offices through Russia, the CIS, the Middle East, Africa, Southeast Asia and LATAM. For more information, please visit the website and follow Nexign on Twitter , Facebook and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006006022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom